|
Realizing the Potential
of CDK 4/6 Inhibitor Therapy in HR+/HER2-
Metastatic Breast Cancer: Managed Care Considerations
on Recent Evidence in Real-World Practice
A continuing medical
education activity sponsored by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
the management of HR+/HER2-metastatic breast cancer
These are archives of live webinars held on December 13, 2021 and
December 17, 2021.
If you participated in any of the live webinars, you are not
eligible to claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all three or in order.
These activities are valid from January 1, 2022 to January 1, 2024
This
series is supported by an educational grant from
Pfizer
Audience:
This activity is intended for healthcare professionals practicing in managed
care environments.
Instructions for CME/NCPD: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
certificate. To print or save your certificate, you will need to click on
the “download” button and either print or save.
Description:
Breast Cancer is the most common cancer found in women, regardless of race or
ethnicity. The incidence in women in the United States is 1 in 8 (about 13
percent). About 43,600 women are expected to die from breast cancer this year,
though death rates have been steadily decreasing over the past 20 years due to
new and ever improving treatment options. However, in the later stages of
disease, when distant metastases are present, cure becomes less likely and few
patients are rendered free of disease. Therapy in the advanced, metastatic
setting then focuses on prolonging life and managing disease-and
treatment-related adverse events. Fortunately for advanced breast cancer
patients with HR+/HER2- advanced breast cancer, several new agents, including
CDK 4/6 inhibitors, have changed the paradigm in the last 10 years, and recent
real-world data has been released that shows the strong efficacy and safety of
these options. With this new data becoming available, it is imperative to
provide medical directors, oncologists, pharmacy directors, oncology case
managers and others on the interprofessional management team with this new data
and best practices on the evolving treatment paradigm, with the ultimate goal of
optimizing access and improving outcomes for patients who would benefit from
these options. |
|
A Closer Look at Recent Real-World and Clinical Trial Data in
the Management of HR+/HER2- Metastatic Breast Cancer: Expert
Perspectives on the Evolving Role of CDK 4/6 Inhibitors
- Examine the unmet clinical needs in HR+/HER2- metastatic breast cancer
and the impact of inadequately treated disease on physical and mental
health, quality of life, costs and work productivity
- Analyze recent efficacy and safety data on CDK 4/6 inhibitors in
HR+/HER2- metastatic breast cancer
- Explore real-world evidence derived from real-world data supplementing
clinical trial evidence related to the benefits and risks of CDK 4/6
inhibitors in HR+/HER2- metastatic breast cancer
- Evaluate best practices for analyzing, interpreting and utilizing
real-world data in addition to data collected from clinical trials related
to CDK 4/6 inhibitors in metastatic breast cancer in terms of study design,
validity, data sources, and implications for everyday managed care and
oncology practice
- Compare and contrast adverse events associated with CDK 4/6 inhibitors
in HR+/HER2- metastatic breast cancer in order to improve patient adherence
and quality of life
Physician, Nursing and CMCN credits valid to
January 1, 2024 |